Search - tctmd.com

Displaying 161 - 180 of 536

Sort: Relevancy | Date

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

L.A. McKeown

February 13, 2023

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

L.A. McKeown

February 02, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

Todd Neale

November 16, 2022

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Advertisement

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Only Half of Revascularized PAD Patients Receive GDMT

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

TCTMD’s Top 10 Most Popular Stories for January 2023

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

January 2023 News Roundup

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

December 2022 News Roundup

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content